Literature DB >> 9102255

Incidence and patterns of recurrence following curative resection for colorectal carcinoma.

D I Obrand1, P H Gordon.   

Abstract

PURPOSE: This study was designed to determine incidence and patterns of recurrence after curative resection of colorectal carcinoma and to determine which variables are significant in predicting outcome.
METHOD: A retrospective review of 524 patients operated on by one surgeon from 1975 to 1992 was conducted. Variables recorded included age, gender, location, gross morphology, histology, stage of each primary and evidence of perforation and direct extension at time of original operation. Overall survival and pattern of recurrence were documented.
RESULTS: Overall recurrence rate was 27.9 percent. Anastomotic recurrence rate was 11.7 percent. Anastomotic recurrences were higher for rectal than colon lesions (20.3 vs. 6.2 percent; P = 0.001). Distant metastases developed in 14.4 percent of patients, 13.9 percent for colon carcinoma and 15.5 percent for rectal carcinoma. Average time for anastomotic recurrence was 16.2 months vs. 22.9 months for distant disease. T1,2,N0,M0 lesions had a 17.6 percent recurrence rate, T3,N0,M0 was 23.4 percent, and T1,2,3,N1,M0 was 43.7 percent (P = .001). Patients who did not undergo any intervention after diagnosis of recurrence survived an average of 28 months. Those who received palliative treatment survived an average of 39 months. Twenty-four percent of patients had reresection for cure, and 47 percent of these patients were alive at a mean of 80 months; those who died of their disease did so at an average of 53 months. Positive predictive factors for recurrence include site of lesion (rectum vs. colon), stage, invasion of contiguous organs, and presence of perforation. Age, gender, degree of differentiation, mucin secretion, and gross morphology were not found to be predictive factors in this study.
CONCLUSIONS: Recurrence after resection for rectal carcinoma is higher than after colon carcinoma. In those patients in whom reresection is possible, up to 50 percent may have long-term survival. Understanding patterns of recurrence and features that predispose to them may guide the physician in aggressive but more selective adjuvant therapy and recommendations for targeted surveillance in follow-up.

Entities:  

Mesh:

Year:  1997        PMID: 9102255     DOI: 10.1007/bf02055676

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  87 in total

1.  Expression of cortactin correlates with a poor prognosis in patients with stages II-III colorectal adenocarcinoma.

Authors:  Jian-hua Cai; Ren Zhao; Jian-wei Zhu; Xiao-long Jin; Fang-jun Wan; Kun Liu; Xiao-pin Ji; Yan-bo Zhu; Zheng-gang Zhu
Journal:  J Gastrointest Surg       Date:  2010-06-08       Impact factor: 3.452

2.  Impact of chemotherapy-related prognostic factors on long-term survival in patients with stage III colorectal cancer after curative resection.

Authors:  Wen-Sy Tsai; Pao-Shiu Hsieh; Chien-Yuh Yeh; Jy-Ming Chiang; Reiping Tang; Jinn-Shiun Chen; Chung Rong Changchien; Jeng Yi Wang
Journal:  Int J Clin Oncol       Date:  2012-01-20       Impact factor: 3.402

3.  Late-occurring liver metastases in colorectal cancer.

Authors:  Francisco Rodríguez-Moranta; Antoni Castells; Rosa Miquel; Virginia Piñol; Joan Maurel; Josep Fuster; Antonio M Lacy; Josep M Piqué
Journal:  Dig Dis Sci       Date:  2005-02       Impact factor: 3.199

4.  Striking similarities in genetic aberrations between a rectal tumor and its lung recurrence.

Authors:  Osama E Rahma; Mauricio Burotto; Luisa Matos Do Canto; Alexandre A Germanos; Bassem R Haddad; John L Marshall
Journal:  World J Gastrointest Oncol       Date:  2013-11-15

Review 5.  New approaches in angiogenic targeting for colorectal cancer.

Authors:  Aleix Prat; Esther Casado; Javier Cortés
Journal:  World J Gastroenterol       Date:  2007-11-28       Impact factor: 5.742

6.  Angiography for diagnosis and treatment of colorectal cancer.

Authors:  Jin Gu; Zhao-Lai Ma; Ying Li; Ming Li; Guang-Wei Xu
Journal:  World J Gastroenterol       Date:  2003-02       Impact factor: 5.742

7.  Reoperation for recurrent colorectal cancer.

Authors:  Michael D Hellinger; Cesar A Santiago
Journal:  Clin Colon Rectal Surg       Date:  2006-11

8.  Health-related quality of life and cost comparison of adjuvant capecitabine versus 5-fluorouracil/leucovorin in stage III colorectal cancer patients.

Authors:  Hong-Hwa Chen; William Tzu-Liang Chen; Hsin-Chung Lee; Jen-Kou Lin; Chuan-Yin Fang; Yenn-Hwei Chou; Peng-Chan Lin; Bo-Wen Lin; Chi-Chou Huang; Chung-Hung Yeh; Hsi-Hsien Hsu; Hung-Chang Chen; Wen-Chien Ting; Ming-Chin Yang; Elise Chia-Hui Tan
Journal:  Qual Life Res       Date:  2014-08-07       Impact factor: 4.147

9.  Metastatic Spermatic Cord Tumor From Colorectal Cancer.

Authors:  Ji Geon Jang; Hye Yun Jeong; Ki Soo Kim; Mi Jung Park; Jin Sook Lee; Sang Su Kim; Ho Young Kim
Journal:  Ann Coloproctol       Date:  2015-10-31

10.  Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer.

Authors:  Christine M Ribic; Daniel J Sargent; Malcolm J Moore; Stephen N Thibodeau; Amy J French; Richard M Goldberg; Stanley R Hamilton; Pierre Laurent-Puig; Robert Gryfe; Lois E Shepherd; Dongsheng Tu; Mark Redston; Steven Gallinger
Journal:  N Engl J Med       Date:  2003-07-17       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.